Ospomyv Injection, Solution
Product Images NDC 83457-012

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ospomyv (NDC 83457-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cordavis Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image (Ospomyv 01)

Image (Ospomyv 01)
This is a set of safety guard components for a medical device. It includes a needle cap, plunger, and finger grip. These components are designed to ensure safe and hygienic use of the device.*
FDA Label Image

Image (Ospomyv 02)

Image (Ospomyv 02)
FDA Label Image

Image (Ospomyv 03)

Image (Ospomyv 03)
FDA Label Image

Image (Ospomyv 04)

Image (Ospomyv 04)
FDA Label Image

Image (Ospomyv 05)

Image (Ospomyv 05)
FDA Label Image

Image (Ospomyv 06)

Image (Ospomyv 06)
FDA Label Image

Figure 1 (Ospomyv 07)

Figure 1 (Ospomyv 07)
This text provides data on patient hip fracture incidence divided by treatment groups over a span of study months. The table presents percentages of hip fracture incidence for the placebo group (N=3906) and the Denosumab group (N=3902) across study months.*
FDA Label Image

Principal Display Panel (60 mg/mL Syringe Carton)

Principal Display Panel (60 mg/mL Syringe Carton)
This text provides detailed information about the medication OSPOMYV™, which is a single-dose pre-filled syringe used for subcutaneous administration by healthcare providers. It contains denosumab-dssb with specific components listed such as histidine, histidine hydrochloride monohydrate, polysorbate 20, sorbitol, and water for injection. The storage instructions are mentioned, advising refrigeration between 2°C to 8°C and potential room temperature storage for up to 60 days after removal from the refrigerator. The dosage and administration frequency are also specified, with OSPOMYV being administered every 6 months. The text recommends discarding unused portions, following prescribing information, and not using the product after the expiration date. For more details or to request additional copies, contact the provided customer service number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.